Cannabis
InterVivo Solutions Issued Institutional Cannabis Research License by Health Canada
Toronto, Ontario–(Newsfile Corp. – February 4, 2021) – InterVivo Solutions Inc. (“InterVivo” or the “Company”), a leading Canadian contract research organization providing preclinical in vivo research services that enable the pharmaceutical and nutraceutical industries to develop new products and therapies for neuropsychiatric and neurological diseases, is pleased to announce that it has been issued an Institution-wide Research License from Health Canada under the Cannabis Act and Cannabis Regulations.
The Institution-wide Research License (IRL) enables InterVivo to conduct multiple studies across all departments at its research facility without the need to apply for study-specific research licenses. Essentially, InterVivo is now granted broad approval to research and develop all cannabis-based products across all of its translational drug discovery services. InterVivo’s clients will benefit with reduced costs, greater study flexibility and shorter turnaround times for their cannabis research & development projects. The IRL will also provide the opportunity to run comparative studies against gold standard cannabinoids such as THC and CBD, as well as interrogate how these classic cannabinoids affect the brain and body.
Joseph Araujo, CEO and Co-Founder of InterVivo commented, “The medicines of the future will ultimately be based on a better understanding of the medicines of the past. As we learn more about how natural cannabinoid molecules work, as well as their limitations as therapies for disease, the better equipped we will be to help our clients design safer and more cost-effective therapies for the growing list of difficult-to-treat neurological conditions. Combined with our in-house expertise in psychedelics research, InterVivo is now poised to help accelerate the next generation of neuroscience drug discovery.”
For more information, please contact:
Sal Lemus
Director of Sales and Marketing
[email protected]
About InterVivo Solutions
InterVivo Solutions (IVS) is Canada’s top neuroscience contract research organization, offering translational research services with a focus on next-generation neuroscience drug discovery. IVS offers in vivo proof of concept efficacy, drug metabolism, pharmacokinetics and early safety research studies for a global client base.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/73691
Cannabis
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
Cannabis
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
Cannabis
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
Cannabis1 week ago
Right on Brands Announces Major Product Line Expansion via HONEY® Brands
-
transfer1 week ago
IMC to transfer its Oranim Pharmacy shares back to the seller
-
Cannabis1 week ago
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
-
Cannabis1 week ago
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
CCELL®2 weeks ago
CCELL Launches Environmentally Conscious Eco Star AIO Vaporizer
-
Innocan4 days ago
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
-
Curaleaf4 days ago
Curaleaf Completes Acquisition of Northern Green Canada
-
Cannabis4 days ago
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care